SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) July 16, 2003
-------------
CollaGenex Pharmaceuticals, Inc.
---------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 0-28308 52-1758016
- -------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
41 University Drive, Newtown, Pennsylvania 18940
- ------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(215) 579-7388
------------------------------------------------
(Registrant's telephone number, including area
code)
----------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS.
On July, 16, 2003, CollaGenex Pharmaceuticals, Inc., a Delaware corporation (the
"Company"), issued a press release announcing it had filed and served a
preliminary injunction in the District Court for the Eastern District of New
York in connection with its patent infringement litigation against United
Research Laboratories/Mutual Pharmaceutical Company ("Mutual"). The Company
previously announced that it had served a complaint in the same court seeking to
prevent Mutual from introducing a 20mg tablet of doxycycline hyclate into the
market in the United States.
The foregoing statements are qualified in their entirety by the Company's press
release, a complete copy of which is filed herewith as Exhibit 99.1 and is
incorporated herein by reference. Item 7. Financial Statements, Pro Forma
Financial Information and Exhibits.
(c) Exhibits.
Exhibit No. Description
----------- ------------
99.1 Press release of CollaGenex Pharmaceuticals, Inc., dated
July 16, 2003.
-2-
SIGNATURES
-----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
COLLAGENEX PHARMACEUTICALS, INC.
By:/s/ Nancy C. Broadbent
--------------------------------------------
Nancy C. Broadbent
Chief Financial Officer
(Principal Financial Officer)
Date: July 16, 2003